Regulatory roles of an atypical ubiquitin ligase UBE2O in orphans of multiprotein complexes for degradation

: UBE2O as an atypical ubiquitin-conjugating enzyme possesses an E2-E3 hybrid enzyme activity. It can regulate substrate levels or transcriptional activities by cooperating with other E3 ubiquitin ligases or forming homomeric complexes displaying intrinsic E2 and E3 activities. UBE2O controls the quality of cell proteome including protein degradation, modification, transport and location. Recent studies reveal that UBE2O plays a vital role in intracellular protein ubiquitination processes by regulating BMP/SMAD, TRAF/ NF-κB, mTOR/HIF1a and IL-1β/IRAK4 signaling pathways, c-Maf stability and BAP1 subcellular location, which is proposed as a quality control supervisor of multiprotein complexes for degradation. Its abnormality leads to a variety of physical activity disorders and even occurrence of cancer. UBE2O is entirely distinct in molecular structure and functions from other E2 ubiquitin ligase. Exploring and elucidating regulatory mechanism of UBE2O may identify novel crucial molecular targets so as to pave therapeutic approaches for ubiquitination-associated metabolic disorders and diseases. Here, we particularly feature regulatory pathways of UBE2O in orphans of multiprotein complexes for degradation and its potential application.

PDF

___

Barton GM, Medzhitov R (2003). Toll-like receptor signaling pathways. Science 300 (5625): 1524-1525.
Briffa R, Um I, Faratian D, Zhou Y, Turnbull AK et al. (2015). MultiScale Genomic, Transcriptomic and Proteomic Analysis of Colorectal Cancer Cell Lines to Identify Novel Biomarkers. PLoS One 10 (12): e0144708.
Cai J, Culley MK, Zhao Y, Zhao J (2018). The role of ubiquitination and deubiquitination in the regulation of cell junctions. Protein Cell 9 (9): 754-769.
Deng L, Wang C, Spencer E, Yang L, Braun A et al. (2000). Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103 (2): 351-361.
Dey A, Seshasayee D, Noubade R, French DM, Liu J et al. (2012). Loss of the tumor suppressor BAP1 causes myeloid transformation. Science 337 (6101): 1541-1546.
Hao YH, Doyle JM, Ramanathan S, Gomez TS, Jia D et al. (2013). Regulation of WASH-dependent actin polymerization and protein trafficking by ubiquitination. Cell 152 (5): 1051-1064.
Hormaechea-Agulla D, Kim Y, Song M, Song S (2018). New Insights into the Role of E2s in the Pathogenesis of Diseases: Lessons Learned from UBE2O. Molecules and Cells 41 (3): 168-178.
Hurt EM, Wiestner A, Rosenwald A, Shaffer AL, Campo E et al. (2004). Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 5 (2): 191-199.
Itoh S, ten Dijke P (2007). Negative regulation of TGF-beta receptor/ Smad signal transduction. Current Opinion in Cell Biology 19 (2): 176-184.
Klemperer NS, Berleth ES, Pickart CM (1989). A novel, arsenitesensitive E2 of the ubiquitin pathway: purification and properties. Biochemistry 28 (14): 6035-6041.
Liang K, Volk AG, Haug JS, Marshall SA, Woodfin AR et al. (2017). Therapeutic Targeting of MLL Degradation Pathways in MLLRearranged Leukemia. Cell 168 (1-2): 59-72 e13.
Markson G, Kiel C, Hyde R, Brown S, Charalabous P et al. (2009). Analysis of the human E2 ubiquitin conjugating enzyme protein interaction network. Genome Research 19 (10): 1905- 1911.
Mashtalir N, Daou S, Barbour H, Sen NN, Gagnon J et al. (2014). Autodeubiquitination protects the tumor suppressor BAP1 from cytoplasmic sequestration mediated by the atypical ubiquitin ligase UBE2O. Molecules and Cells 54 (3): 392-406.
Meyer C, Hofmann J, Burmeister T, Groger D, Park TS et al. (2013). The MLL recombinome of acute leukemias in 2013. Leukemia 27 (11): 2165-2176.
Misaghi S, Ottosen S, Izrael-Tomasevic A, Arnott D, Lamkanfi M et al. (2009). Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. Molular and Cellular Biology 29 (8): 2181-2192.
Miyazono K, Kamiya Y, Morikawa M (2010). Bone morphogenetic protein receptors and signal transduction. Journal of Biochemistry 147 (1): 35-51.
Mohan M, Lin C, Guest E, Shilatifard A (2010). Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nature Reviews Cancer 10 (10): 721-728.
Nguyen AT, Prado MA, Schmidt PJ, Sendamarai AK, WilsonGrady JT et al. (2017). UBE2O remodels the proteome during terminal erythroid differentiation. Science 357: eaan0218. Pigneux A, Labopin M, Maertens J, Cordonnier C, Volin L et al. (2015). Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML). Leukemia 29 (12): 2375-2381.
Plouhinec JL, Zakin L, De Robertis EM (2011). Systems control of BMP morphogen flow in vertebrate embryos. Current opinion in genetics and development 21 (6): 696-703.
Sieber C, Kopf J, Hiepen C, Knaus P (2009). Recent advances in BMP receptor signaling. Cytokine Growth Factor Review 20 (5-6): 343-355.
Sowa M E, Bennett EJ, Gygi S P, Harper JW (2009). Defining the human deubiquitinating enzyme interaction landscape. Cell 138 (2): 389-403.
Tsuchida S, Satoh M, Takiwaki M, Nomura F (2017). Ubiquitination in Periodontal Disease: A Review. International Journal of Molecular Science 18 (7): 1476.
Ullah K, Zubia E, Narayan M, Yang J, Xu G (2019). Diverse roles of the E2/E3 hybrid enzyme UBE2O in the regulation of protein ubiquitination, cellular functions, and disease onset. The FEBS Journal 286 (11): 2018-2034.
van Wijk SJ, Timmers HT (2010). The family of ubiquitin-conjugating enzymes (E2s): deciding between life and death of proteins. Federation of American Societies for Experimental Biology 24 (4): 981-993.
Vila IK, Song SJ, Song MS (2017). A new duet in cancer biology: AMPK the typical and UBE2O the atypical. Molecular & Cellular Oncology 4 (3): e1304846.
Vila IK, Yao Y, Kim G, Xia W, Kim H et al. (2017). A UBE2OAMPKalpha2 Axis that Promotes Tumor Initiation and Progression Offers Opportunities for Therapy. Cancer Cell 31 (2): 208-224.
Wang C, Deng L, Hong M, Akkaraju GR, Inoue J et al. (2001). TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412 (6844): 346-351.
Xing Y, Yao X, Li H, Xue G, Guo Q et al. (2017). Cutting Edge: TRAF6 Mediates TLR/IL-1R Signaling-Induced Nontranscriptional Priming of the NLRP3 Inflammasome. Journal of Immunology 199 (5): 1561-1566.
Xu Y, Zhang Z, Li J, Tong J, Cao B et al. (2017). The ubiquitinconjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis. Journal of Hematologyand Oncology 10 (1): 132.
Yanagitani K, Juszkiewicz S, Hegde RS (2017). UBE2O is a quality control factor for orphans of multiprotein complexes. Science 357 (6350): 472-475.
Yokota T, Nagai H, Harada H, Mine N, Terada Y et al. (2001). Identification, tissue expression, and chromosomal position of a novel gene encoding human ubiquitin-conjugating enzyme E2-230k. Genetics 267 (1): 95-100.
Yu H, Mashtalir N, Daou S, Hammond-Martel I, Ross J et al. (2010). The ubiquitin carboxyl hydrolase BAP1 forms a ternary complex with YY1 and HCF-1 and is a critical regulator of gene expression. Molecular and Cellular Biology 30 (21): 5071-5085.
Zhang X, Zhang J, Bauer A, Zhang L, Selinger DW et al. (2013). Finetuning BMP7 signalling in adipogenesis by UBE2O/E2-230Kmediated monoubiquitination of SMAD6. EMBO Journal 32 (7): 996-1007.
Zhang X, Zhang J, Zhang L, van Dam H, ten Dijke P (2013). UBE2O negatively regulates TRAF6-mediated NF-kappaB activation by inhibiting TRAF6 polyubiquitination. Cell Research 23 (3): 366-377.
Zhang Z, Tong J, Tang X, Juan J, Cao B et al. (2016). The ubiquitin ligase HERC4 mediates c-Maf ubiquitination and delays the growth of multiple myeloma xenografts in nude mice. Blood 127 (13): 1676-1686.
Zhou F, Zhang X, van Dam H, Ten Dijke P, Huang H, Zhang L (2012). Ubiquitin-specific protease 4 mitigates Toll-like/interleukin-1 receptor signaling and regulates innate immune activation. Journal of Biological Chemistry 287 (14): 11002-11010.